- Home
- IROQ vs GALT Comparison
IROQ vs GALT Comparison
Compare IROQ & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IROQ
- GALT
- Stock Information
- Founded
- IROQ 1883
- GALT 2000
- Country
- IROQ United States
- GALT United States
- Employees
- IROQ N/A
- GALT N/A
- Industry
- IROQ Savings Institutions
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- IROQ Finance
- GALT Health Care
- Exchange
- IROQ Nasdaq
- GALT Nasdaq
- Market Cap
- IROQ 79.7M
- GALT 83.5M
- IPO Year
- IROQ 2011
- GALT N/A
- Fundamental
- Price
- IROQ $24.70
- GALT $2.60
- Analyst Decision
- IROQ
- GALT Buy
- Analyst Count
- IROQ 0
- GALT 2
- Target Price
- IROQ N/A
- GALT $6.00
- AVG Volume (30 Days)
- IROQ 1.6K
- GALT 1.2M
- Earning Date
- IROQ 04-29-2025
- GALT 08-12-2025
- Dividend Yield
- IROQ 1.60%
- GALT N/A
- EPS Growth
- IROQ 69.23
- GALT N/A
- EPS
- IROQ 1.05
- GALT N/A
- Revenue
- IROQ $25,099,000.00
- GALT N/A
- Revenue This Year
- IROQ N/A
- GALT N/A
- Revenue Next Year
- IROQ N/A
- GALT N/A
- P/E Ratio
- IROQ $23.85
- GALT N/A
- Revenue Growth
- IROQ 12.02
- GALT N/A
- 52 Week Low
- IROQ $14.85
- GALT $0.73
- 52 Week High
- IROQ $25.76
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- IROQ 53.16
- GALT 70.66
- Support Level
- IROQ $24.37
- GALT $1.28
- Resistance Level
- IROQ $24.96
- GALT $1.36
- Average True Range (ATR)
- IROQ 0.24
- GALT 0.33
- MACD
- IROQ 0.05
- GALT 0.18
- Stochastic Oscillator
- IROQ 61.83
- GALT 52.40
About IROQ IF Bancorp Inc.
IF Bancorp Inc is a holding company. It is mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company with the association take deposits from the general public and invest those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, others and also a variety of deposit accounts and alternative delivery channels.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.